0JV0.F iBio, Inc.
- Market cap
- EUR 32.3M
- P/E
- -
- P/B
- 0.59x
- ROE
- -38.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 0JV0.F undervalued?
Graham numberThe Graham number of iBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
iBio, Inc. fundamental analysis
No fundamental analysis for iBio, Inc. yet.
iBio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large…
Full company profileiBio, Inc. financial statements
iBio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.88M | 0.00 | 225K | 400K | 100K |
| Gross Profit | 2.17M | - | - | - | - |
| Operating Income | -29.7M | -29.3M | -16.6M | -18.6M | -30.1M |
| EBITDA | - | -27.8M | -14.0M | -17.0M | -32.0M |
| Net Income | -50.4M | -65.0M | -24.9M | -18.4M | -33.0M |
| EPS | -115 | -64 | -2.89 | -0.95 | -0.59 |
| Balance Sheet | |||||
| Total Assets | 99.4M | 41.2M | 28.7M | 23.2M | 99.1M |
| Total Liabilities | 35.9M | 25.8M | 7.41M | 8.31M | 13.4M |
| Shareholders' Equity | 63.5M | 15.4M | 21.3M | 14.9M | 85.7M |
| Cash & Short-term Investments | 22.7M | 4.30M | 14.2M | 8.58M | 56.4M |
| Cash Flow | |||||
| Operating Cash Flow | -37.5M | -30.4M | -18.6M | -15.3M | -23.2M |
| Capital Expenditure | 11.6M | 5.74M | 210K | 16.0K | 578K |
| Free Cash Flow | -49.1M | -36.2M | -18.8M | -15.3M | -23.8M |
| Ratios | |||||
| ROE | -79.4% | -422.7% | -116.8% | -123.5% | -38.6% |
| ROA | -50.7% | -157.8% | -86.7% | -79.3% | -33.3% |
| Net Profit Margin | -2,674.7% | - | -11,069.8% | -4,594.3% | -33,044.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
iBio, Inc. dividends
iBio, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Nov 29, 2023.
Who owns iBio, Inc.
- Insiders 1.32%
- Institutions 64.37%
- Public & others 34.31%
- Shares outstanding 49.7M
- Free float 46.1M
iBio, Inc. company profile
- Company name
- iBio, Inc.
- Ticker
- 0JV0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- June
- Address
- 11750 Sorrento Valley Road, San Diego, CA, United States, 92121
- Phone
- 979 446 0027
- Website
- ibioinc.com
About iBio, Inc.
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
iBio, Inc. management
4- Dr. Martin B. Brenner D.V.M., Ph.D.CEO, Chief Scientific Officer & Director · born 1970
- Mr. Felipe DuranCFO & Principal Accounting Officer · born 1979
- Mr. Marc Banjak J.D.Chief Legal Officer & Corporate Secretary · born 1977
- Dr. Molly Carr M.D.Chief Medical Officer · born 1967